Compare Autodesk Inc (ADSK) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autodesk Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Autodesk Inc trades at $250.44 (market cap $54.07B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B). The key difference: Autodesk Inc is far larger — about 5.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Autodesk Inc nearer its low. Which is the better fit depends on your goals.
| ADSK | BIO | |
|---|---|---|
Market Cap | $54.07B | $9.39B |
Sector | Technology | Health |
52-Week High | $326.79 | $356.25 |
52-Week Low | $187.72 | $241.71 |
Enterprise Value | $53.87B | $9.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $249.08, up 2.73% on the day, with a bullish technical signal and strong fundamental performance. Revenue grew to $6.13B in 2025, with net income reaching $1.11B and a 19.49% net margin. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $2.99 exceeding the $2.84 forecast. Analyst consensus is a Buy with a $305.31 price target, supported by 74.51% of analysts rating it a Buy. Recent news highlights AI investments and strategic acquisitions.
Outlook remains positive given robust earnings growth, high profitability margins, and strategic AI investments. Risks include competitive pressures in software, reliance on economic cycles affecting design software demand, and execution risks from recent acquisitions. The stock offers upside to the consensus target but faces volatility near technical resistance at $253.
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
